Full-Time

Staff Scientist ADPE

Protein Sciences

Posted on 2/10/2025

Alector

Alector

51-200 employees

Biopharmaceutical R&D for neurodegenerative therapies

Compensation Overview

$181.1k - $188.3k/yr

San Bruno, CA, USA

In Person

The job is onsite, indicating that it requires in-person presence.

Category
Biology & Biotech (2)
,
Requirements
  • PhD in protein biochemistry with 5+ years or MS with 10+ years of therapeutic protein production experience
  • Proven hands-on expertise in various protein characterization methods and tools including SDS-PAGE, WB, LAL, CE-SDS, Analytical SEC and RP-HPLC, SEC-MALS, DLS, DSF and mass spectrometry
  • Expert in protein purification using affinity, IEX, HIC and mixed-mode chromatography
  • Capable of designing protein purification strategies and troubleshooting problems independently
  • Experience with generating difficult-to-produce, low-expressing intracellular, membrane and/or secreted fusion proteins
  • Familiarity with standard text, graphic, and presentation software is required and database/data archival software systems is helpful
  • Excellent interpersonal, communication and presentation skills
  • Self-motivated and a creative problem solver
  • Low ego with a point of view
Responsibilities
  • Implement expression/purification/conjugation processes to generate protein reagents at milligram to gram level scales
  • Manage, coordinate, and run developability assessment requests
  • Collaborate extensively across functions and contribute to prioritization and planning within group and project teams to meet company goals
  • Accurately and clearly document experimental notes, protocols, and results
  • Present results at project team and departmental meetings
  • Support development of novel technologies, including high-throughput capabilities, for protein production, analytical, and characterizations
  • Prepare to learn and grow in a highly productive, fun and collaborative environment!
Desired Qualifications
  • Expertise in high throughput purification technologies is a plus
  • Expertise in various site-specific ASO or SiRNA bio-conjugation techniques and DAR determination is a plus

Alector is a biopharmaceutical company that develops therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. It uses insights from immunology, neurology, and human genetics to create medicines that help the body heal itself. The company focuses on researching and developing novel therapeutic candidates, mainly through early-stage clinical trials to quickly gather disease-specific data and improve the chances of success. Revenue and funding come from partnerships, grants, and eventual product commercialization. Alector aims to advance treatments for unmet medical needs in neurodegenerative diseases by pursuing a pipeline that combines scientific findings with strategic drug development.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2013

Your Connections

People at Alector who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AL037/AL137-ABC anti-amyloid antibody targets validated epitope with reduced ARIA risk versus competitors.
  • Cash position of $206.5 million funds operations through 2027 and preclinical pipeline advancement.
  • Analyst consensus price target 48% above current stock price signals potential undervaluation opportunity.

What critics are saying

  • AL002 Phase 2 failure and GSK latozinemab efficacy stumble eliminate two major clinical assets.
  • Hercules Capital debt covenants trigger default from Q1 2026 revenue miss, forcing $10M repayment.
  • 13% workforce layoff signals cash constraints and accelerates talent exodus to better-funded competitors.

What makes Alector unique

  • Proprietary Alector Brain Carrier technology enables blood-brain barrier penetration for siRNA and protein therapeutics.
  • Genetically-validated target selection from human genetics, neuroscience, and immunology insights reduces clinical failure risk.
  • AL050 GCase enzyme replacement therapy addresses GBA mutations in Parkinson's and Lewy body dementia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

5%

2 year growth

7%
Yahoo Finance
Feb 25th, 2026
Alector beats Q4 expectations with $6.2M revenue, narrows loss to 34 cents per share

Alector, a South San Francisco-based biotechnology company, reported a fourth-quarter loss of $37.3 million, or 34 cents per share, beating analyst expectations of a 39-cent loss. The company posted revenue of $6.2 million, exceeding forecasts of $3.1 million from three analysts surveyed by Zacks Investment Research. For the full year, Alector's loss widened to $142.9 million, or $1.39 per share, with revenue of $21 million. The company's shares closed at $2.39 on Wednesday, up from $1.77 a year earlier.

GlobeNewswire
Jun 3rd, 2025
Alector To Participate In The Goldman Sachs 46Th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET.A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.About AlectorAlector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline

Stock Titan
May 6th, 2025
Alector to Participate in Upcoming Healthcare Conferences

Additionally, Alector will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York on May 20, 2025, at 12:00 p.m. ET.

ITTBioMed
Apr 2nd, 2025
New breakthroughs in early-onset dementia: progranulin therapies show promise

In another strategy, Alector, in collaboration with GSK, is developing the monoclonal antibody latozinemab (AL001), which works by blocking progranulin degradation to boost its availability.

BioSpace
Mar 25th, 2025
Alector Cuts Staff Again, This Time Laying Off 13% of Workforce

As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and research pipeline.

INACTIVE